Alnylam Pharmaceuticals Reports Strong 2024 Financial Results and Outlines Ambitious 2025 Pipeline Advancements

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...

February 14, 2025 | Friday | News
AstraZeneca CEO Pascal Soriot Leads Strong FY 2024 Growth with 21% Revenue Surge and Ambition 2030 in Focus

AstraZeneca delivered $54.1 billion in total revenue for FY 2024, a 21% increase at constant exchange rates (CER), fueled by strong growth across oncolog...

February 07, 2025 | Friday | Company results
Illumina’s CEO Jacob Thaysen Drives Strategic Growth as Q4 Revenue Surpasses Expectations

      Illumina, led by CEO Jacob Thaysen, delivered a Q4 revenue of $1.1 billion, reflecting a steady 1% year-over-year increase, w...

February 07, 2025 | Friday | Company results
BD Reports Strong Q1 2025 Results with $5.2B Revenue as CEO Tom Polen Announces Strategic Business Separation

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,  announced its financial results for the first quarter ...

February 06, 2025 | Thursday | Company results
Merck (Known as MSD Outside the U.S. & Canada) Reports Strong 2024 Growth – CEO Robert M. Davis Highlights KEYTRUDA, WINREVAIR, and Pipeline Momentum

Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth W...

February 04, 2025 | Tuesday | Company results
Albert Bourla Leads Pfizer to $63.6B Triumph in 2024 – Record Growth, Bold Strategy, and a Sharpened Vision for 2025!

Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...

February 04, 2025 | Tuesday | Company results
Novartis Posts 12% Sales Growth in 2024 as CEO Vas Narasimhan Sets Sights on Stronger 2025

Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from Ent...

January 31, 2025 | Friday | Company results
Lonza Delivers CHF 6.6 Billion in 2024 Sales as CEO Wolfgang Wienand Drives One Lonza Strategy

In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1) CORE EBITDA of CHF 1.9 billion at a margin of 29.0% The CDMO...

January 31, 2025 | Friday | Company results
Marc N. Casper on Thermo Fisher's Strong 2024 Finish: "We Drove Meaningful Growth, Positioned for Excellence in 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year...

January 30, 2025 | Thursday | Company results
Roche Reports Positive Two-Year Results from EMBARK Trial for Elevidys™, First Gene Therapy for Duchenne Muscular Dystrophy

Roche announced  positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (de...

January 28, 2025 | Tuesday | News
Sotera Health Reports 5% Growth in 2024 Revenue, Provides Business Update at J.P. Morgan Healthcare Conference

 Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-...

January 15, 2025 | Wednesday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Lilly’s Pirtobrutinib Shows Strong Efficacy in Phase 3 BRUIN CLL-321 Trial for BTK-Inhibitor Pre-Treated CLL/SLL Patients

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...

December 10, 2024 | Tuesday | News
bluebird bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Listing Compliance

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...

December 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close